

D<sup>2</sup> 32. (Twice Amended) The method of Claim 28 further comprising exposing a cell to a second anti-ErbB2 antibody which does not bind to an epitope on ErbB2 to which antibody 7C2 or 7F3 bind.

D<sup>3</sup> 34. (Twice Amended) The method of Claim 33 wherein the cell is exposed to the antibody that binds to an epitope on ErbB2 to which antibody 7C2 or 7F3 bind before the cell is exposed to the second antibody.

D<sup>4</sup> 42. (Twice Amended) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of a composition comprising an antibody that binds to an epitope on ErbB2 to which antibody 7C2 or 7F3 bind and a pharmaceutically acceptable carrier, wherein the antibody results in about 5 to 50 fold induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells.

D<sup>5</sup> 58. (Twice Amended) A method for inducing cell death comprising:  
exposing a cell that overexpresses ErbB2 to a first antibody that binds to an epitope on ErbB2 to which antibody 7C2 or 7F3 bind; and  
subsequently exposing the cell to a second antibody that binds to a domain of ErbB2 other than the binding site of antibody 7C2 or 7F3.

Please add the following new claims:

D<sup>6</sup> 59. (New) The method of Claim 42, wherein said antibody is selected from the group consisting of a chimeric antibody, a polyclonal antibody, a monoclonal antibody and a humanized antibody.

60. (New) The method of Claim 42, wherein the antibody induces cell death via apoptosis.